β¨ Medicines Act Notices
1832 NEW ZEALAND GAZETTE No. 69
Health
Medicines Act 1981
Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Atovaquone 250 mg | Tablet | Wellcome Foundation Limited, Temple Hill, Dartford, Kent, United Kingdom | Wellvone |
Note: This medicine may only be distributed, supplied, or used under conditions to be imposed from time to time by the Director-General of Health.
Dated this 9th day of July 1995.
DAVID SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.
g03587
Consent to the Distribution of a New Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Flucloxacillin sodium equivalent to 250 mg, 500 mg or 1 g flucloxacillin | Powder for injection (vials) | CT Laboratorio, San Remo, Italy and IBSA SA, Lugano, Switzerland | Flucloxacillin for injection |
| Vincristine sulphate 1 mg/mL in 1 mL, 2 mL and 5 mL | Solution for IV injection (vials) | Delta West Pty Limited, Bentley, Western Australia, Australia | Vincristine Sulphate Injection |
| Methadone hydrochloride 5 mg/5 mL in 200 mL and 1000 mL | Syrup | Wellcome Australia Limited, Cabarita, New South Wales, Australia | Methadone |
| Miconazole nitrate 2.5 mg/g, zinc oxide 150 mg/g in 15 g | Ointment | Janssen Pharmaceutica nv., Beerse, Belgium | Daktozin |
| Isofluorane 100% in 100 mL | Liquid (volatile inhalant) | Ohmeda Caribe Inc., Guayama, Puerto Rico | Aerrane |
| Pethidine hydrochloride 50 mg, 100 mg | Tablet | Douglas Pharmaceuticals Limited, Mount Roskill, Auckland |
Note: Not to be marketed as substitutable for any other pethidine hydrochloride product as if the two (2) products were bioequivalent.
Dated this 9th day of July 1995.
DAVID SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.
g04585
Consent to the Distribution of a New Related Product
Pursuant to section 96 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new related product set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name |
|---|---|---|---|
| Potassium nitrate 50 mg, sodium fluoride 2.25 mg per gm | Toothpaste | Packaging Corporation of America, Los Angeles, California, United States of America and Chempac Liquid, Division of CCL Industries, Etobicoke, Ontario, Canada | Oral-B Sensitive with Fluoride |
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1995, No 69
NZLII —
NZ Gazette 1995, No 69
β¨ LLM interpretation of page content
π₯ Provisional Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare9 July 1995
Medicines Act, Provisional Consent, Atovaquone, Wellvone
- DAVID SMYTH, Acting Director-General of Health
π₯ Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare9 July 1995
Medicines Act, Consent to Distribution, Flucloxacillin, Vincristine, Methadone, Miconazole, Isofluorane, Pethidine
- DAVID SMYTH, Acting Director-General of Health
π₯ Consent to the Distribution of a New Related Product
π₯ Health & Social Welfare9 July 1995
Medicines Act, Consent to Distribution, Potassium nitrate, sodium fluoride, Oral-B Sensitive with Fluoride
- DAVID SMYTH, Acting Director-General of Health